TY - JOUR
T1 - Predictors of duloxetine response in patients with neuropathic cancer pain
T2 - a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study
AU - Matsuoka, Hiromichi
AU - Iwase, Satoru
AU - Miyaji, Tempei
AU - Kawaguchi, Takashi
AU - Ariyoshi, Keisuke
AU - Oyamada, Shunsuke
AU - Satomi, Eriko
AU - Ishiki, Hiroto
AU - Hasuo, Hideaki
AU - Sakuma, Hiroko
AU - Tokoro, Akihiro
AU - Matsuda, Yoshinobu
AU - Tahara, Kazuki
AU - Otani, Hiroyuki
AU - Ohtake, Yoichi
AU - Tsukuura, Hiroaki
AU - Matsumoto, Yoshihisa
AU - Hasegawa, Yoshikazu
AU - Kataoka, Yuki
AU - Otsuka, Masatomo
AU - Sakai, Kiyohiro
AU - Nakura, Miki
AU - Morita, Tatsuya
AU - Yamaguchi, Takuhiro
AU - Koyama, Atsuko
N1 - Funding Information:
This work was supported by the following grants: Sasakawa Memorial Health Foundation Research Grant (Grant No.: 2013-A003), 2014-2017 Grant-in-Aid for Scientific Research (Grant-in-Aid for Young Scientists B; Grant No.: 26860486), 2014 Health Labour Sciences Research Grant (Grant for Innovative Clinical Cancer Research: H26-Innovative Cancer-General-056; Grant No.: 16ck0106059h0003), 2015-2016 Japan Agency for Medical Research and Development (AMED) award (Innovative Clinical Cancer Research; Grant No.: 17ck0106328h0001), and a 2017 Japan Agency for Medical Research and Development (AMED) award (Innovative Clinical Cancer Research; Grant No.: 18ck0106328h0002). The authors thank in advance all the patients, investigators, and institutions involved in this study.
Funding Information:
Sasakawa Health Foundation Nippon Foundation Building 5F,1-2-2 Akasaka, Minato-ku,Tokyo 107-0052, Japan Phone: 81-3-6229-5377 Fax: 81-3-6229-5388 Health Labour Sciences Research Grant 5-3-1 Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan Phone: 81-3-5253-4111 Ministry of Health, Labour and Welfare 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan Minato-ku,Tokyo 107-0052, Japan Phone: 81-3-5253-1111 Japan Agency for Medical Research and Development 22F Yomiuri Shimbun Bldg. 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004 Japan Minato-ku,Tokyo 107-0052, Japan Phone: 81-3-6870-2221 Fax: 81-3-6870-2244 CNP Cancer neuropathic pain NP Neuropathic pain IASP International Association for the Study of Pain BPI-SF item 5 Brief pain inventory item 5 CIPN Chemotherapy-induced peripheral neuropathy HADS Hospital anxiety and depression scale JORTC Japanese Organization for Research and Treatment of Cancer PCS Pain catastrophizing scale SF-MPQ Short-form McGill pain questionnaire Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Purpose: Duloxetine has some effect against cancer neuropathic pain (CNP); however, predictors of duloxetine response are unclear. This study sought to identify predictors of duloxetine response in patients with CNP. Methods: Patients (N = 70) with CNP unresponsive to or intolerant of opioid–pregabalin combination therapy, with a brief pain inventory-short form (BPI-SF) Item 5 score (average pain) ≥ 4, and with a total hospital anxiety and depression scale score < 20, were randomized to a duloxetine or a placebo group. Multiple linear regression analysis was conducted to identify predictors of duloxetine response as a secondary analysis with the change in the average pain score on day 10 from day 0 as the dependent variable, and the following five covariates; baseline (day 0) average pain score, baseline opioid dose, continuation/discontinuation of pregabalin, and items 20 and 21 score of the short-form McGill pain questionnaire 2 (SF-MPQ-2) as independent variables. Results: Of the four domains (continuous pain, intermittent pain, neuropathic pain, and affective descriptors) score of SF-MPQ-2 on day 0, significant differences were observed in the neuropathic pain domain (p = 0.040) in change on the average pain between day 10 and day 0 in the duloxetine group. Multiple linear regression analysis revealed that patients with a high score for SF-MPQ-2 Item 21 (tingling pain) on day 0 had a significantly greater change in average pain between day 10 and day 0 (p = 0.046). Conclusion: Patients with a high score for SF-MPQ-2 Item 21 might benefit more from duloxetine.
AB - Purpose: Duloxetine has some effect against cancer neuropathic pain (CNP); however, predictors of duloxetine response are unclear. This study sought to identify predictors of duloxetine response in patients with CNP. Methods: Patients (N = 70) with CNP unresponsive to or intolerant of opioid–pregabalin combination therapy, with a brief pain inventory-short form (BPI-SF) Item 5 score (average pain) ≥ 4, and with a total hospital anxiety and depression scale score < 20, were randomized to a duloxetine or a placebo group. Multiple linear regression analysis was conducted to identify predictors of duloxetine response as a secondary analysis with the change in the average pain score on day 10 from day 0 as the dependent variable, and the following five covariates; baseline (day 0) average pain score, baseline opioid dose, continuation/discontinuation of pregabalin, and items 20 and 21 score of the short-form McGill pain questionnaire 2 (SF-MPQ-2) as independent variables. Results: Of the four domains (continuous pain, intermittent pain, neuropathic pain, and affective descriptors) score of SF-MPQ-2 on day 0, significant differences were observed in the neuropathic pain domain (p = 0.040) in change on the average pain between day 10 and day 0 in the duloxetine group. Multiple linear regression analysis revealed that patients with a high score for SF-MPQ-2 Item 21 (tingling pain) on day 0 had a significantly greater change in average pain between day 10 and day 0 (p = 0.046). Conclusion: Patients with a high score for SF-MPQ-2 Item 21 might benefit more from duloxetine.
KW - Duloxetine
KW - Neuropathic cancer pain
KW - Palliative care
KW - Randomized controlled trial
KW - Secondary analyses
UR - http://www.scopus.com/inward/record.url?scp=85075403873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075403873&partnerID=8YFLogxK
U2 - 10.1007/s00520-019-05138-9
DO - 10.1007/s00520-019-05138-9
M3 - Article
C2 - 31761974
AN - SCOPUS:85075403873
SN - 0941-4355
VL - 28
SP - 2931
EP - 2939
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 6
ER -
